Uncertainty over the timing of the Labosite product’s inclusion in OECD guidelines and its impact on sales
First written in FY2018. 2 of 4 entries say "Mitigated", first in FY2019-Q1. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual reportIn the FY2024 business risk section, no standalone item can be identified addressing uncertainty over the timing of LabCyte's OECD guideline listing and its revenue impact.
- FY2019MitigatedAnnual report
「The eye irritation test method using Cornea-Model 24 was included in OECD Test Guideline 492 (TG492) in June 2018, followed by the inclusion of the skin corrosion test method including Epi-Model 24 in OECD Test Guideline 431 (TG431) in June 2019.」
Regarding the uncertainty over the timing of inclusion in OECD guidelines, which had previously been a risk, the inclusion of TG431 following TG492 further reduced the uncertainty surrounding inclusion. - FY2019-Q1MitigatedAnnual report
「In June 2018, the eye irritation test method using LabCyte Cornea-Model 24 was included in Test Guideline 492 of the Organisation for Economic Co-operation and Development (OECD), OECD TG492.」
Regarding the uncertainty over the timing of inclusion in OECD guidelines, which had previously been a risk, the inclusion of the test method for Cornea Model 24 in TG492 in June 2018 reduced the portion of the risk relating to delays in inclusion. Uncertainty remains regarding the revenue impact after inclusion. - FY2018First statedAnnual report
「Although we are working to establish an OECD Test Guideline for the in vitro eye irritation test method, the method may not be included in the Test Guidelines within the scheduled period, or even if it is included, revenue may not increase as expected.」
The delay in listing the corneal model under an OECD guideline and the possibility that its revenue impact after listing will fall short of expectations were disclosed as standalone risks.